Diagnostic contribution of 18F-FDG-PET/CT in fever of unknown origin  by Tokmak, Handan et al.
International Journal of Infectious Diseases 19 (2014) 53–58Diagnostic contribution of 18F-FDG-PET/CT in fever of
unknown origin
Handan Tokmak a, Onder Ergonul b,*, Onur Demirkol b, Mustafa Cetiner b,
Burhan Ferhanoglu b
aAmerican Hospital, Istanbul, Turkey
b School of Medicine, Koc¸ University, Istanbul, Turkey
A R T I C L E I N F O
Article history:
Received 23 July 2013
Received in revised form 31 August 2013
Accepted 9 October 2013
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Fever of unknown origin (FUO)
18F-FDG-PET/CT
Vasculitis
Inﬂammatory non-infectious disease
Imaging follow-up of FUO
S U M M A R Y
Objectives: Fever of unknown origin (FUO) remains one of the most compelling diagnostic issues in
medicine. We aimed to evaluate the potential clinical contribution of 18-ﬂuoro-2-deoxyglucose positron
emission tomography/computed tomography (18F-FDG-PET/CT) in the identiﬁcation of the underlying
cause of FUO.
Methods: Fifty consecutive patients (27 men and 23 women; age range 16–88 years) with FUO based on
the revised deﬁnition criteria were included in the study. A diagnostic protocol including biochemistry,
histopathology, and microbiological tests was performed and the patients were followed up. FDG-PET
was performed in 25 of the 50 patients (12 males and 13 females; age range 16–88 years) in order to
determine the etiology of the patient’s fever. PET-CT images were obtained with the Gemini Philips TF
18F-FDG-PET/CT camera after a 60-min ‘standard uptake’ period following an injection of a mean 330
MBq (range 290–370 MBq) intravenous 18F-FDG.
Results: A total of 21 patients were available for analysis of the diagnostic contribution of PET/CT (two
patients were undiagnosed and two had non-contributory PET/CT ﬁndings). 18F-FDG-PET/CT was able to
precisely detect the cause of fever in 60% of the cases (n = 15). The accuracy, sensitivity, and speciﬁcity of
this imaging modality were 90.5%, 93.8%, and 80%, respectively. Among the cases with a true-positive
18F-FDG-PET/CT ﬁnding (i.e., 15 cases), the identiﬁed underlying causes of FUO included localized
infection (n = 7), non-infective inﬂammatory process (n = 5), and malignancy (n = 3).
Conclusions: Further studies to conﬁrm the high diagnostic yield of 18F-FDG-PET/CT observed in the
present study would lend support to the inclusion of this imaging modality in the initial diagnostic work-
up of patients with suspected FUO.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Identiﬁcation of the etiology of fever of unknown origin (FUO) is
crucial in guiding further diagnostic procedures and subsequent
patient management. The standard diagnostic approach includes
repeated laboratory tests, imaging procedures, and other conven-
tional examinations, which are generally time-consuming and
frequently inconclusive. In this regard, it is important to note that a* Corresponding author at: Koc¸ University, School of Medicine, Infectious
Diseases Department, Istanbul, Turkey.
E-mail addresses: oergonul@ku.edu.tr, oergonul@gmail.com (O. Ergonul).
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http://dx.doi.org/10.1016/j.ijid.2013.10.009multitude of studies have been performed in the last decade to
evaluate the diagnostic role of 18-ﬂuoro-2-deoxyglucose positron
emission tomography/computed tomography (18F-FDG-PET/CT) in
FUO.1–7
Generally, these studies have emphasized the usefulness and
advantages of 18F-FDG-PET/CT in terms of providing better
diagnostic accuracy as compared to other standard diagnostic
approaches, mostly likely owing to its ability to assess the
morphology and functional characteristics of the tissues simulta-
neously.8–13 The metabolic properties of 18F-FDG allow 18F-FDG-
PET/CT to reﬂect the status of the intracellular glucose metabolism
successfully. This property of 18F-FDG-PET/CT is especially useful
for elucidating equivocal structural abnormalities through assess-
ment of the metabolic activity, or for deﬁning inﬂammatory
processes that are difﬁcult to examine through the use of
conventional imaging modalities.14–16ciety for Infectious Diseases. Open access under CC BY-NC-ND license.
H. Tokmak et al. / International Journal of Infectious Diseases 19 (2014) 53–5854In this study, the predictive diagnostic value of 18F-FDG-PET/CT
imaging in FUO was explored.
2. Patients and methods
2.1. Patients
A total of 50 consecutive patients admitted to the American
Hospital between 2008 and 2012 with a clinical suspicion of FUO
were included in this retrospective observational study. Twenty-
ﬁve of the 50 patients underwent PET/CT examination at the
discretion of the physician, without the use of a speciﬁc protocol.
Patient data were retrieved from the hospital records.
FUO was deﬁned as a temperature greater than 38 8C on several
occasions, a duration of illness of more than 3 weeks, and no
identiﬁed diagnosis despite 1 week of inpatient investigation.10,11
The latter criterion has recently been modiﬁed and is now
generally interpreted as no established diagnosis after adequate
inpatient or outpatient evaluation.17 Patients with an active
malignancy, neutropenia, or nosocomial infections were not
included in the study.
2.2. Basic diagnostic evaluation
After a comprehensive history was obtained (including
information on travel, occupation, and sexual history) and a
physical examination was performed, a series of laboratory
investigations for FUO was also carried out for all participants,
including routine blood tests (complete blood count, erythrocyte
sedimentation rate (ESR), renal and hepatic function tests,
electrolytes, creatinine phosphokinase, and lactate dehydroge-
nase), urinalysis, chest radiography, abdominal ultrasonography,
Brucella serum tube agglutination, Gruber–Widal agglutination,
peripheral blood smear, anti-nuclear and anti-neutrophilic cyto-
plasmic antibodies, rheumatoid factor, and blood and urine
cultures. When deemed necessary, the following tests were also
done: cultures other than blood and urine, serologic tests for
cytomegalovirus (CMV) IgM, Epstein–Barr virus (EBV), Salmonella,
Brucella, Coxiella burnetii, Toxoplasma, rubella, herpes, and
hepatitis A, B, and C viruses, echocardiography, computerized
tomography (CT), magnetic resonance imaging (MRI), histopatho-
logical examination, and peripheral smear for malaria. PET/CT was
used at the discretion of the physician without a speciﬁc protocol.
The ﬁnal diagnosis was based on the results of histopathology,
microbiological or serologic assays, and/or long-term clinical and
imaging follow-up.
2.3. 18F-FDG-PET/CT imaging
In those undergoing a PET/CT examination, whole body scans
were performed (deﬁned as from the top of the head through the
mid-thigh), and if clinically indicated, was extended to total body
imaging, including the extremities. Additionally, a low-dose CT
was performed in order to process attenuation correction (CT-AC),
or it was used for anatomical co-registration of PET ﬁndings. 18F-
FDG-PET/CT images were acquired 60 min after the intravenous
injection of 18F-FDG, using an 18F-FDG-PET/CT combined with a
third-generation multi-slice spiral CT scanner with a dedicated
full-ring PET scanner, which had a high count rate capability
lutetium yttrium oxyorthosilicate (LYSO)-based camera with time-
of-ﬂight (TOF) technology. Emission scans of 18F-FDG-PET/CT were
acquired in 3D mode, from head to mid-thigh. PET and CT images
(non-corrected and attenuation-corrected) were evaluated in the
rotating maximum-intensity projection and in the cross-sectional
planes view (transverse–sagittal–coronal). The images with
increased focal uptake with higher intensity than the surroundingtissues, not corresponding to physiological distribution of 18F-FDG,
were deﬁned as positive.
2.4. Interpretation of data
Patients were followed-up for 12 months. True-positivity (TP)
was deﬁned as an 18F-FDG-PET/CT study demonstrating a focal 18F-
FDG-positive lesion, which subsequently proved to be causative of
the FUO. False-positivity (FP) was deﬁned as hypermetabolic
activity that could not be associated with an inﬂammatory/
infectious process causing FUO at the time of the initial
examination or during the 12-month follow-up period. Normal
ﬁndings with a physiological FDG accumulation were recorded as
true-negative (TN) when no localized disease process was
diagnosed and there were no ﬁndings of disease identiﬁed during
follow-up. On the other hand, in the event that a focal infectious
process, non-infectious inﬂammatory process, or malignancy was
identiﬁed during clinical investigation within the 30-day period
following a negative 18F-FDG-PET/CT, the outcome was interpreted
as false-negative (FN). The diagnostic accuracy, sensitivity, and
speciﬁcity of the test were deﬁned as follows: diagnostic accuracy,
(TP + TN)/(TP + TN + FP + FN); sensitivity, TP/(TP + FN); speciﬁcity,
TN/(FP + TN).
3. Results
The characteristics of the patients who underwent PET/CT
imaging and the diagnostic contribution of PET/CT are presented in
Table 1. Of the 25 patients, four were not available for diagnostic
value estimations. In two of these, a ﬁnal diagnosis could not be
established, thus they were categorized as ‘undiagnosed’. One of
the patients in the ‘undiagnosed’ category had bilateral hypermet-
abolic mediastinal lymphadenopathy and increased FDG uptake in
the mediastinal lymph nodes, but did not consent to a biopsy. The
other patient, who had anemia in conjunction with fever, had a
negative PET/CT scan (except for non-speciﬁc ﬁndings), and the
fever subsided in several weeks without an established deﬁnitive
diagnosis. Two other patients who were categorized as ‘non-
contributory’ due to negative PET/CT scans (except for non-speciﬁc
ﬁndings) were subsequently diagnosed with Still’s disease without
a speciﬁc focus.
18F-FDG-PET/CT was able to detect the cause of fever precisely
in 60% (n = 15) of the patients. Among the 21 patients in whom the
diagnostic role of 18F-FDG-PET/CT could be assessed, the results
were categorized as follows: 15 true-positive, four true-negative,
one false-positive, and one false-negative. Thus, the estimated
accuracy, sensitivity, and speciﬁcity of 18F-FDG-PET/CT were 90.5%,
93.8%, and 80%, respectively.
Among the true-positive cases, the following underlying causes
of FUO were identiﬁed: localized infection in seven patients, non-
infective inﬂammatory process in ﬁve patients, and malignancy in
three patients. The subsequent diagnoses in true-negative cases
included one patient with a chronic urinary tract infection with no
focal 18F-FDG accumulation, one patient with FMF (Familial
Mediterranean fever), and two other patients with spontaneous
disappearance of fever. In these latter cases, there were no
additional ﬁndings suggestive of an etiological factor during the
clinical follow-up. One patient with an initial positive 18F-FDG-
PET/CT result was subsequently categorized as ‘false-positive’. This
patient, who had increased skeletal uptake and multiple lymph
nodes, was later diagnosed with anti-phospholipid syndrome and
was treated successfully with corticosteroid therapy. Also, there
was one false-negative result in a single patient with an ultimate
diagnosis of temporal arteritis with negative 18F-FDG-PET/CT
ﬁndings.
Table 1
Patient characteristics and the results of diagnostic procedures
Age, years Gender Imaging ﬁndings Results of additional relevant
diagnostic procedures
Contribution of PET/CT Final diagnosis Result Disease group
81 M Diffuse bone marrow activity increase Inconclusive CT ﬁndings Non-contributory Temporal arteritis FN Rheumatologic
55 F Increased spleen activity plus low FDG
avid non-speciﬁc lymph nodes
Inconclusive CT ﬁndings Improved diagnostic approach, many
causes if fever excluded
Anti-phospholipid syndrome FP Rheumatologic
65 M Inhomogeneously increased skeletal
and diffuse bone marrow uptake
None Improved diagnostic approach Still’s disease Non-contributory Rheumatologic
62 F Increased bone marrow plus spleen
activity
None Non-contributory Undiagnosed (anemia but no reason
found for fever), spontaneous recovery
Undiagnosed N
76 F Symmetrical hypermetabolic
mediastinal lymph nodes
Mediastinal lymph nodes Patient did not accept the biopsy
(otherwise, PET/CT would guide for
biopsy site)
Undiagnosed Undiagnosed N
33 F Heterogeneous increase in bone
marrow and spleen activity
None Improved diagnostic approach Still’s disease Non-contributory Rheumatologic
75 M Non-speciﬁc None Non-contributory Chronic urinary tract infection TN Infectious
80 F Physiological FDG distribution None Improved diagnostic approach (by
excluding fever causes)
Not diagnostic TN N
81 F Physiological FDG distribution Inconclusive CT ﬁndings Improved diagnostic approach (by
excluding fever causes)
Not diagnostic TN N
45 M Physiological FDG distribution Inconclusive CT ﬁndings Improved diagnostic approach (by
excluding fever causes)
Familial Mediterranean fever TN Rheumatologic
58 F Periarticular uptake Inconclusive CT ﬁndings Leading criteria to ﬁnal diagnosis Polymyalgia rheumatica TP Rheumatologic
58 M Vascular prosthesis (20 years ago) Inconclusive CT ﬁndings Aided in diagnosis and guided for
surgical approach
Infective prosthetic graft TP Infectious
37 M Pleural activity Inconclusive CT ﬁndings (pleural
thickening)
Guided biopsy Pleuritis TP Infectious
70 F Sub-hepatic focal uptake Inconclusive CT ﬁndings (history of
abdominal surgery)
Aided in diagnosis and guided for
treatment (removal of catheter)
Shunt infection TP Infectious
56 F Maxillary uptake CT ﬁndings of sinusitis Other more likely fever causes were
excluded, determined the need for
antibiotic treatment
Sinusitis TP Infectious
55 M L3–5 soft tissue Previous vertebral operation plus
pacemaker (contraindication for MRI)
Guided biopsy Spondylitis TP Infectious
66 F Lung uptake Inconclusive CT ﬁndings Guided biopsy Tuberculosis TP Infectious
60 F Soft tissue uptake None Guided biopsy Panniculitis TP Infectious
54 M Hypermetabolic cervical mediastinal
lymph nodes
None Guided biopsy and established
diagnosis (at the very early stage)
Acute myeloid leukemia TP Neoplastic
24 F Hypermetabolic brain lesions plus
multiple hypermetabolic lymph nodes
Complicated CT ﬁndings Showed brain lesions plus guided
biopsy plus helpful in the evaluation of
treatment response
Lymphoma and tuberculosis TP Neoplastic
16 M Heterogeneous bone marrow uptake
plus hypermetabolic skin lesion
None Guided biopsy and established
diagnosis
Acute myeloid leukemia TP Neoplastic
75 M Tendon adjunction None Guided biopsy Enthesopathy TP Rheumatologic
53 F Vasculitis Inconclusive CT ﬁndings Guided biopsy Giant cell vasculitis TP Rheumatologic
62 F Soft tissue uptake in deep gluteal fat
tissue
None Guided for identiﬁcation of the biopsy
site
Panniculitis TP Rheumatologic
88 M Increased periarticular uptake None Guided biopsy Polymyalgia rheumatica TP Rheumatologic
F, female; FDG, ﬂuorodeoxyglucose; FN, false-negative; FP, false-positive; M, male; MRI, magnetic resonance imaging; N, None; PET/CT, positron emission tomography/computed tomography; TN, true-negative; TP, true-positive.
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H. Tokmak et al. / International Journal of Infectious Diseases 19 (2014) 53–5856The ﬁnal diagnoses among the other 25 patients admitted to our
institution during the study period who did not undergo PET/CT
examination were as follows: infection in 13 patients, rheumato-
logic disease in six patients, and malignancy in four patients; two
patients remained undiagnosed.
4. Discussion
The diagnostic performance of 18F-FDG-PET/CT in detecting a
focal etiology in patients with FUO is generally assessed based on
certain parameters, such as the sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV). The
initial work-up usually includes standard laboratory, histopathol-
ogy, microbiological–immunological assays, or conventional ana-
tomic imaging modalities, i.e. ultrasound, CT, and MRI.
Unfortunately, these standard approaches generally exhibit a
relatively low sensitivity and speciﬁcity, particularly during the
early stages of disease.8–10 In this study, the estimated diagnosticFigure 1. 18F-FDG-PET/CT images of a patient with a histologicaccuracy, sensitivity, and speciﬁcity of 18F-FDG-PET/CT for FUO
were 90.5%, 93.8%, and 80%, respectively. The 18F-FDG-PET/CT
demonstrates better accuracy owing to its ability to carry out
morphological and functional assessments concomitantly, in
contrast to the conventional diagnostic modalities.18–22 18F-
FDG-PET/CT facilitates an early diagnosis not only by indicating
the best biopsy site, but also through altering the traditional
clinical perspective by providing morphological and functional
hybrid imaging of the whole body.23 In complicated patients in
particular, determining the underlying cause of FUO is often a
vexing diagnostic challenge for the clinician, as was the case with
our Hodgkin lymphoma patient who also had systemic tuberculo-
sis. In this challenging case, 18F-FDG-PET/CT revealed positive
ﬁndings in the brain and supra- and infra-diaphragmatic lymph
nodes, along with heterogeneous lung uptake and hepatospleno-
megaly. In this patient, laboratory ﬁndings were non-speciﬁc but
they suggested the presence of lymphoma. Bone marrow and
lymph node pathology conﬁrmed a diagnosis of diffuse large B cellally established diagnosis of acute monoblastic leukemia.
H. Tokmak et al. / International Journal of Infectious Diseases 19 (2014) 53–58 57lymphoma. Tuberculosis had initially been suspected based on
pulmonary ﬁndings and accompanying encephalopathy, but
bronchoscopy revealed bronchopulmonary lavage ﬂuid with
negative Ziehl–Neelsen staining. Pathological examination of the
axillary lymph nodes showed necrotic granulomas and diffuse
invasion of lymphocytes with atypical nuclei. Patients with
malignant lymphoma are known to be vulnerable to tuberculosis,
and 18F-FDG-PET/CT imaging has provided a major contribution to
the ﬁnal diagnosis by indicating the best possible biopsy sites and
showing diffuse pathological ﬁndings. Furthermore, 18F-FDG-PET/
CT ﬁndings have subsequently proved to be crucial in the
evaluation of the outcome of treatment.
The diagnosis of acute monoblastic leukemia (AML) as the
etiology of FUO requires a high index of suspicion due to its
infrequent occurrence and non-speciﬁc symptomatology. Two
patients in our series were diagnosed with AML (Figure 1). TheyFigure 2. 18F-FDG-PET/CT images revealed diffusely increased 18F-FDG uptake in a circ
subclavian, and common iliac arteries.had vague and non-speciﬁc symptoms such as fever, fatigue,
weight loss or loss of appetite, shortness of breath, and anemia.
18F-FDG-PET/CT was extremely useful in the diagnosis of these
patients through monitoring 18F-FDG in the skin lesions and bone
marrow.
Speciﬁcally, 18F-FDG-PET/CT has been useful in both positive and
negative cases. The two patients showing an inhomogeneous
increased 18F-FDG uptake throughout the axial and appendicular
skeleton had no further evidence of pathology at biopsy. According
to previous reports, increased bone marrow 18F-FDG uptake may be
a consequence of interleukin-dependent upregulation of glucose
transporters rather than the underlying etiology of FUO.21Two of the
patients with increased 18F-FDG uptake throughout the axial and
appendicular skeleton were diagnosed with Still’s disease. 18F-FDG-
PET/CT provided useful information for further management beyond
the traditional medical perspective, although it did not contributeumferential fashion along the aorta and its major branches, including the carotid,
H. Tokmak et al. / International Journal of Infectious Diseases 19 (2014) 53–5858speciﬁcally to the ﬁnal diagnosis. An increased FDG uptake in the
mediastinal lymph nodes was found in another patient (female,
aged 76 years). However, this patient did not consent to a
biopsy, thus a ﬁnal diagnosis could not be established. Nevertheless,
in non-speciﬁc inﬂammatory processes involving soft tissues or
lymph nodes, increased metabolic activity has been described
previously.16
Giant cell vasculitis may be associated with non-speciﬁc
symptoms, as in one of the patients in our series (Figure 2), and
it comprises 17% of all FUO cases.10 In our group, the corresponding
ﬁgure for giant cell vasculitis was 8%. A high NPV has previously
been reported for FDG-PET/CT in the diagnosis of large vessel
vasculitis, with a sensitivity ranging between 77% and 92% and
speciﬁcity ranging between 89% and 100%.24–27 Even in this group,
where the possibility of focal disease is ruled out, 18F-FDG-PET/CT
offers a useful contribution to the diagnostic work-up of large
vessel vasculitis.
In the present study, 18F-FDG-PET/CT has been found to provide
valuable information, facilitating a ﬁnal diagnosis or ruling out a
focal pathology in patients with FUO. Even a negative PET/CT was
useful in terms of guiding further management strategies. The
present ﬁndings reported for 21 patients with high accuracy,
sensitivity, and speciﬁcity provides further supporting evidence to
the already existing literature data for the use of this speciﬁc
imaging modality in suspected FUO cases.28,29 For example, in a
prospective multicentre study, Keidar et al.5 evaluated the role of
18F-FDG-PET/CT in 48 patients with FUO; in that study PET/CT
identiﬁed the underlying cause of the fever in 46% of the study
population and contributed to the diagnosis or exclusion of a focal
pathological etiology of the febrile state in 90% of patients, with a
high NPV (100%) for the assessment of FUO. Together with the
results reported in a multitude of retrospective studies, the high
sensitivity and speciﬁcity of FDG-PET/CT suggests that this
imaging technique represents a promising diagnostic procedure
for the detection of the underlying cause of FUO. In this regard, it
may be worth looking at the PPV/NPV rates reported by Balink
et al.,2 Pelosi et al.,13 and Crouzet et al.,29 which were 93%/100%,
85%/91%, and 93%/100%, respectively.
Several studies have suggested a higher cost-effectiveness for
PET/CT in suspected FUO when used in the early stages.30
Considering its high cost, the routine use of PET/CT for this
indication is unlikely to occur in the near future. On the other hand,
the liberal use of this approach in centers like ours where PET/CT is
available could provide useful information in the management of
FUO cases. Furthermore, the use of this modality for the evaluation
of patients with FUO would not raise serious concerns about
radiation exposure, since the CT component of PET/CT imaging is
associated with a low radiation exposure, which is within
acceptable limits and similar to the dose a typical patient with
FUO would receive during routine radiological investigations.
In conclusion 18F-FDG-PET/CT has an incremental diagnostic
value in the diagnosis and management of FUO. In the future, 18F-
FDG-PET/CT may well be included in the initial diagnostic work-up
for the investigation of the etiology of FUO.
Conﬂict of interest: The authors declare that they do not have any
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